| Name | Title | Contact Details |
|---|
LaBelle Strategic Resources is a Collegeville, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
In July 2014, Genoa Healthcare and QoL meds combined to create Genoa, a QoL Healthcare Company, the nation`s leading behavioral health specialty pharmacy company. This merger brought together two pharmacy organizations with proven track records for excellent service to individuals with mental illness. Both companies had strong reputations for outstanding customer service, flexibility and delivering true value to their consumers and partners. By uniting their strengths – like best practices and expertise – the combined company was able to better serve individuals and the health organizations that care for them over the past year. Genoa has been serving the behavioral health community for over 15 years. The company now provides specialty behavioral health and long-term care pharmacy services to more than 500,000 individuals annually, operating over 285 pharmacies in 39 states and the District of Columbia and filling more than 9 million prescriptions per year. Although Genoa specializes in serving behavioral health consumers, we are a full-service pharmacy. This means we take care of all the medication needs of our consumers, including prescriptions written by psychiatrists, primary care providers, or other specialty prescribers. Genoa remains flexible to the many behavioral health and primary care delivery models across the country and developed services within our pharmacies to meet the needs of those specific models. None of our service models or pharmacies are the same. We take pride in not being a "cookie cutter" organization, and continue to seek opportunities nationwide to help behavioral health communities with their pharmacy services.
Senior Access is a San Rafael, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.
DisperSol Technologies provides expertise in formulation and processing technologies for solubility/bioavailability enhancement of poorly water-soluble drug molecules.